Rosebud Biosciences accelerates drug development by screening drugs against organoids (micro-organs) that have the same gene mutations as the patients. We partner with therapeutics companies to screen their drugs, and we perform our own drug discovery for rare diseases that have no existing treatments. Our organoids are also fetal-like and enable discovery of novel drug targets for pediatric diseases. This technology was validated at Stanford, published in a prestigious journal, and has already led to the discovery of a drug target in a pediatric heart disease that could not have been found using traditional disease models.
Evan is co-founder and CTO of Rosebud Biosciences. Evan is a Scientist-Engineer (PhD) with 10 years’ experience in advanced microscopy, machine learning, and data engineering. At UC Berkeley he studied the neural coding of perception and was part of a team that built the first bidirectional brain machine interface with proven single cell resolution. Before joining Rosebud he contracted for startups as a data and ML engineer.
Kitch is co-founder and CEO of Rosebud Biosciences. He is a Physician-Scientist (MD, PhD) with 14 years’ experience merging human induced pluripotent stem cells with genomic and molecular technologies. A Stanford-trained molecular pathologist, Kitch was an attending physician at Stanford for 6 years. He applied for and won multiple grants, including a 5-year career development award (NIH K08), and led postdocs, grad students and technicians to publish 4 first-author papers while on the faculty.
Drug discovery for pediatric genetic diseases
Kitch (CEO) began working full-time on the business plan and ideas for Rosebud’s platform technology in June 2020. Evan joined full-time as cofounder and CTO in January 2021.